INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation
FRA:IUI1 • US46120E6023
Current stock price
413.65 EUR
-10.05 (-2.37%)
Last:
This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IUI1.DE Profitability Analysis
1.1 Basic Checks
- In the past year IUI1 was profitable.
- In the past year IUI1 had a positive cash flow from operations.
- In the past 5 years IUI1 has always been profitable.
- Each year in the past 5 years IUI1 had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 13.96%, IUI1 belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
- IUI1 has a better Return On Equity (16.02%) than 87.69% of its industry peers.
- The Return On Invested Capital of IUI1 (13.95%) is better than 89.23% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is in line with the industry average of 10.72%.
- The 3 year average ROIC (12.43%) for IUI1 is below the current ROIC(13.95%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROIC | 13.95% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
1.3 Margins
- IUI1 has a better Profit Margin (28.38%) than 100.00% of its industry peers.
- IUI1's Profit Margin has improved in the last couple of years.
- The Operating Margin of IUI1 (29.35%) is better than 96.92% of its industry peers.
- In the last couple of years the Operating Margin of IUI1 has grown nicely.
- IUI1 has a Gross Margin of 66.00%. This is in the better half of the industry: IUI1 outperforms 73.85% of its industry peers.
- In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% |
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
2. IUI1.DE Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
- Compared to 1 year ago, IUI1 has less shares outstanding
- Compared to 5 years ago, IUI1 has more shares outstanding
- IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 41.47 indicates that IUI1 is not in any danger for bankruptcy at the moment.
- IUI1 has a Altman-Z score of 41.47. This is amongst the best in the industry. IUI1 outperforms 100.00% of its industry peers.
- There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 41.47 |
ROIC/WACC1.39
WACC10.05%
2.3 Liquidity
- A Current Ratio of 4.87 indicates that IUI1 has no problem at all paying its short term obligations.
- With an excellent Current ratio value of 4.87, IUI1 belongs to the best of the industry, outperforming 96.92% of the companies in the same industry.
- A Quick Ratio of 3.96 indicates that IUI1 has no problem at all paying its short term obligations.
- IUI1 has a better Quick ratio (3.96) than 96.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 |
3. IUI1.DE Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 21.83% over the past year.
- The Earnings Per Share has been growing by 21.42% on average over the past years. This is a very strong growth
- The Revenue has grown by 20.51% in the past year. This is a very strong growth!
- Measured over the past years, IUI1 shows a quite strong growth in Revenue. The Revenue has been growing by 18.22% on average per year.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
3.2 Future
- Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.58% on average per year.
- Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 12.90% on average per year.
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. IUI1.DE Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 53.51, IUI1 can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 61.54% of the companies are valued more cheaply.
- When comparing the Price/Earnings ratio of IUI1 to the average of the S&P500 Index (25.70), we can say IUI1 is valued expensively.
- With a Price/Forward Earnings ratio of 46.73, IUI1 can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 69.23% of the companies are valued more cheaply.
- The average S&P500 Price/Forward Earnings ratio is at 23.84. IUI1 is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.51 | ||
| Fwd PE | 46.73 |
4.2 Price Multiples
- 67.69% of the companies in the same industry are cheaper than IUI1, based on the Enterprise Value to EBITDA ratio.
- IUI1's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 68.1 | ||
| EV/EBITDA | 45.45 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
- IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
- IUI1's earnings are expected to grow with 14.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.7
PEG (5Y)2.5
EPS Next 2Y14.34%
EPS Next 3Y14.52%
5. IUI1.DE Dividend Analysis
5.1 Amount
- No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
IUI1.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:IUI1 (3/13/2026, 7:00:00 PM)
413.65
-10.05 (-2.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22 2026-01-22/amc
Earnings (Next)04-20 2026-04-20/amc
Inst Owners88.53%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap146.90B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts78.1
Price Target527.49 (27.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)-1.16%
PT rev (3m)0.59%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)0.27%
EPS NY rev (1m)0%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)1.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.51 | ||
| Fwd PE | 46.73 | ||
| P/S | 16.85 | ||
| P/FCF | 68.1 | ||
| P/OCF | 55.97 | ||
| P/B | 9.52 | ||
| P/tB | 9.73 | ||
| EV/EBITDA | 45.45 |
EPS(TTM)7.73
EY1.87%
EPS(NY)8.85
Fwd EY2.14%
FCF(TTM)6.07
FCFY1.47%
OCF(TTM)7.39
OCFY1.79%
SpS24.54
BVpS43.47
TBVpS42.52
PEG (NY)3.7
PEG (5Y)2.5
Graham Number86.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.96% | ||
| ROE | 16.02% | ||
| ROCE | 16.01% | ||
| ROIC | 13.95% | ||
| ROICexc | 20.73% | ||
| ROICexgc | 21.4% | ||
| OM | 29.35% | ||
| PM (TTM) | 28.38% | ||
| GM | 66% | ||
| FCFM | 24.75% |
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 79.72% | ||
| Cap/Sales | 5.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.46% | ||
| Profit Quality | 87.21% | ||
| Current Ratio | 4.87 | ||
| Quick Ratio | 3.96 | ||
| Altman-Z | 41.47 |
F-Score8
WACC10.05%
ROIC/WACC1.39
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.56%
EBIT Next 3Y21.57%
EBIT Next 5Y17.26%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%
INTUITIVE SURGICAL INC / IUI1.DE Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 1 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.
Can you provide the financial health for IUI1 stock?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.